Palo Alto, CA Clinical Trials Report — June 2026

For residents of Palo Alto, CA, considering participation in clinical research, June 2026 presents a mix of urgent opportunities and promising new avenues for contributing to medical science. With a significant number of trials nearing their enrollment deadlines, prompt action is essential for interested individuals.

Currently, 34 clinical trials in Palo Alto are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Urgent Opportunities in Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Behavior, Child (2 trials)
• Developmental Disability (2 trials)
• Diabetes Mellitus, Type 1 (2 trials)
• Ovarian Cancer (2 trials)
• Leukemia (2 trials)
• Gastric Cancer (2 trials)
• Child Development (2 trials)
• Age-Related Macular Degeneration (1 trial)
• Advanced Breast Cancer (1 trial)
• Acute Lymphoblastic Leukemia (1 trial)

New Research Horizons in Palo Alto

This month, Palo Alto saw the opening of 10 new clinical trials, a slight decrease from the 12 trials that launched in May 2026. Despite this, the city remains a vibrant research hub with a total of 578 actively recruiting clinical trials across 166 research facilities.

June brings several high-profile new trials to Palo Alto, including significant Phase 2 and 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Pfizer is initiating a notable Phase 3 study, NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants." This study aims for 3,230 participants to evaluate the safety and effectiveness of a new pneumococcal vaccine in infants against infections like pneumonia, meningitis, and otitis media.
• Yan Mia Min is sponsoring NCT07671469, "Personalized Blood Transfusion Protocol for Cardiac Patients." This study, involving 900 participants, compares two methods for determining when adults recovering from open-heart surgery should receive a blood transfusion in the intensive care unit.
• Stanford University is leading NCT07661563, "Advancing Scalable Alcohol Brief Interventions in the ED: A Trial of Conversational AI With Digital Reinforcements." This trial, with 750 participants, investigates if a digital strategy combining generative AI counseling and weekly SMS boosters can reduce risky drinking among Emergency Department patients.
• AngioInsight is sponsoring NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational study aims for 620 participants to establish the diagnostic performance of the AngioAI+ System for estimating fractional flow reserve and detecting coronary microvascular disease.
• AstraZeneca is conducting NCT07647328, "A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer." This Phase 3b study, with 150 participants, investigates the efficacy, safety, and tolerability of camizestrant in combination with ribociclib for patients with advanced breast cancer who have not received prior systemic treatment for advanced disease.
• AusperBio Therapeutics Inc. is leading NCT07654283, "Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions." This Phase 2 trial, involving 70 participants, evaluates the efficacy and safety of AHB-137 injection in individuals with chronic hepatitis B treated with Nucleos(t)ide Analogue (NAs).

New trials this month are exploring a range of conditions, including abdominal pain, acute myeloid leukemia, acute or chronic coronary artery disease, alcohol misuse, anemia, blood transfusion, cardiac surgery, cardiopulmonary bypass, chronic pain, and complex regional pain syndromes. Drug trials account for the largest share of new studies, with 4 new drug trials, followed by 2 behavioral studies and 2 biological studies.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 10 new trials launched this month, 2 are actively seeking healthy volunteers. Across Palo Alto, a total of 54 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Palo Alto's Leading Research Facilities

Palo Alto is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Stanford University (132 trials)
• Stanford Cancer Institute Palo Alto (39 trials)
• Lucile Packard Children's Hospital Stanford University (24 trials)
• Stanford University Medical Center (24 trials)
• Palo Alto Medical Foundation Health Care (23 trials)
• VA Palo Alto Health Care System (23 trials)
• Stanford Cancer Institute (21 trials)
• Stanford University School of Medicine (19 trials)
• Lucile Packard Children's Hospital (19 trials)
• Stanford Cancer Center (19 trials)

These institutions offer a broad spectrum of research, from comprehensive studies at Stanford University and its Medical Center, to specialized care at Stanford Cancer Institute and Lucile Packard Children's Hospital. The VA Palo Alto Health Care System also plays a crucial role in local research efforts.

Broadening Your Search: Nearby Options

While Palo Alto offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within California. Cities with active trials include Los Angeles (31 trials), San Francisco (17 trials), San Diego (16 trials), La Jolla (9 trials), Stanford (7 trials), Sacramento (6 trials), Duarte (6 trials), and Walnut Creek (6 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 9 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children. Academic institutions continue to play a vital role in Palo Alto's research ecosystem, with Stanford University sponsoring 4 of the new studies. Industry sponsors like AstraZeneca, AusperBio Therapeutics Inc., AngioInsight, and Pfizer are also driving significant research efforts.

As we move through June, Palo Alto's dynamic research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.